Optimization of chemo- and radiotherapy in the first line treatment of Hodgkin lymphoma

Abstract

Hodgkin lymphoma is a disease with good prognosis. Using modern combined modalities, such as chemo- and radiotherapy, up to 90% of patients with limited-stage disease can be cured. However 20–30% of patients with advanced disease fail to achieve durable remission. ABVD has been considered in many countries as a standard treatment. This standard is currently challenged by more intensive BEACOPP protocol. To reduce toxicity without loosing efficacy there are many attempts to tailor therapy using clinical prognostic factors or PET guided therapy. This article summarizes current possibilities of first line treatment of Hodgkin lymphoma with chemo- and radiotherapy.